Form 4: Ionis Director Exercises, Sells Stock Under 10b5-1 Plan

Ionis Pharmaceuticals Director Joseph Loscalzo exercised stock options and sold common stock on March 3 and 4, 2026, under a pre-arranged 10b5-1 trading plan.

Summary

• Joseph Loscalzo, a Director of IONIS PHARMACEUTICALS INC (IONS), reported transactions involving the company's common stock and non-qualified stock options.
• On March 3, 2026, Loscalzo acquired 832 shares of common stock by exercising non-qualified stock options at an exercise price of $38.06 per share.
• Immediately following the acquisition on March 3, 2026, Loscalzo sold 832 shares of common stock at a weighted average price of $80.3279 per share. These shares were sold in multiple transactions ranging from $80.035 to $81.01.
• On March 4, 2026, Loscalzo acquired an additional 200 shares of common stock by exercising non-qualified stock options at an exercise price of $38.06 per share.
• Following this acquisition on March 4, 2026, Loscalzo sold 200 shares of common stock at a price of $80 per share.
• All sales were conducted pursuant to a Rule 10b5-1 Trading Plan adopted by Loscalzo on November 18, 2025.
• After these transactions, Loscalzo beneficially owns 36,330 shares of common stock and 10,968 non-qualified stock options.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral event. While a director sold shares, it was pre-planned under a 10b5-1 plan, and the exercise of options indicates value realization, which is a routine part of executive compensation.

Positives

• The director exercised options at a significantly lower price ($38.06) and sold shares at a much higher market price (approximately $80-$81), indicating a profitable transaction for the insider.
• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, which suggests a systematic approach to managing personal holdings rather than a reaction to immediate company news.

Negatives

• The director's sale of common stock, even under a 10b5-1 plan, represents a reduction in direct equity holdings, which some investors might interpret as a lack of increased confidence, though it is a common practice for liquidity and diversification.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider transactions, particularly sales under 10b5-1 plans, are common for executives to manage personal finances and diversify holdings without necessarily implying a lack of confidence in the company's future. These plans are designed to allow insiders to sell shares at pre-determined times or prices to avoid accusations of trading on material non-public information.

Stakeholder Impact

• Shareholders: Provides transparency into a director's stock holdings and transactions, which is standard regulatory disclosure.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions under a pre-arranged 10b5-1 plan, which are common for executives to manage personal liquidity and diversification. The transactions themselves do not provide new fundamental information about Ionis Pharmaceuticals' operational performance or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as the filing does not present a compelling reason to buy or sell based solely on these insider activities.

Keywords

Ionis Pharmaceuticals, IONS, Form 4, Insider Trading, Stock Options, 10b5-1 Plan, Director Transactions, Joseph Loscalzo